- Home
- LXEH vs MBRX Comparison
LXEH vs MBRX Comparison
Compare LXEH & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | MBRX |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.1M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | LXEH | MBRX |
|---|---|---|
| Price | $0.21 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | ★ 515.3K | 229.4K |
| Earning Date | 05-01-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.25 |
| 52 Week High | $50.08 | $7.98 |
Technical Indicators
Market Signals| Indicator | LXEH | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 33.10 |
| Support Level | $0.19 | $0.37 |
| Resistance Level | $0.28 | $5.22 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 9.37 | 42.62 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.